Inpharma 1487 - 14 May 2005

■ Squalamine, in combination with photodynamictherapy with verteporfin (PDT), may stabilise vision inage-related macular degeneration (AMD), according tointerim results from a phase II study presented at theAssociation for Research in Vision and OphthalmologyAnnual Meeting in Fort Lauderdale, Florida, US. Forty-six patients with AMD were randomised to receive asingle IV infusion of squalamine 10–40mg in weeks 1,2, 4 and 5 in addition to PDT at week 3 (n = 29), orPDT alone. Relative to baseline, mean increases invisual acuity of 1.5 ETDRS** letters were observed inboth the squalamine and control groups at week 3.The mean changes in visual acuity of evaluable studyeyes at week 9 were +1.3 and –0.9 ETDRS letters inthe squalamine and control groups, respectively;corresponding values for those with a fellow affectedeye were –1.9 and –4 ETDRS letters.* Genaera Corporation; phase II for AMD in the US** Early Treatment Diabetic Retinopathy Study

Genaera Corporation. Genaera Announces Positive Interim EVIZON(TM)Phase II (MSI-1256F-208) AMD Data at Annual ARVO Meeting. MediaRelease : 3 May 2005. Available from: URL: http://www.genaera.com 809048669

1

Inpharma 14 May 2005 No. 14871173-8324/10/1487-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved